Online inquiry

IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2284MR)

This product GTTS-WQ2284MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Graft-versus-host disease (GvHD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ2284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11467MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ10208MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ10702MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ9373MR IVTScrip™ mRNA-Anti-IL2R, Interleukin 2(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Interleukin 2
GTTS-WQ13559MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ5241MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ9623MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ15324MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW